Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2012
03/01/2012WO2012025942A1 Methods for the treatment or prophylaxis of thrombosis or embolism
03/01/2012WO2012025940A1 Polymorphic form of ivabradine hydrochloride and process for preparation thereof
03/01/2012WO2012025937A1 Improved process for preparation of sugammadex
03/01/2012WO2012025912A1 Synergistic fungicidal composition
03/01/2012WO2012025877A1 Proline sulfonamide derivatives as orexin receptor antagonists
03/01/2012WO2012025857A1 Cycloalkyl methoxybenzyl phenyl pyran derivatives as sodium dependent glucose co transporter (sglt2) inhibitors
03/01/2012WO2012025811A1 Indolylpyrimidines as modulators of gpr119
03/01/2012WO2012025762A2 Pure intermediate
03/01/2012WO2012025761A1 Theobromine in combination with an expectorant or a mucolytic for use in therapy
03/01/2012WO2012025726A1 Novel Hybrid Compounds
03/01/2012WO2012025701A1 Alpha, alpha - di substituted glycine ester derivatives and their use as hdac inhibitors
03/01/2012WO2012025638A1 Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
03/01/2012WO2012025591A1 Process for the manufacture of a highly enriched extract containing zeaxanthin and/or its esters
03/01/2012WO2012025474A1 Indazole compounds
03/01/2012WO2012025473A1 Cc.chemokine receptor 4 antagonists
03/01/2012WO2012025460A1 Oxadiazolinone derivatives and use thereof in pest control
03/01/2012WO2012025251A1 Nucleic acids for treatment of chronic complications of diabetes
03/01/2012WO2012025239A1 Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012WO2012025238A1 Substituted quinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012WO2012025237A1 Substituted 2-amino-quinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012WO2012025236A1 Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators
03/01/2012WO2012025229A1 Composition and method of manufacture
03/01/2012WO2012025217A1 Novel use of leflunomide and malononitrilamides
03/01/2012WO2012025186A1 Triazolopyrazine derivatives
03/01/2012WO2012025164A1 Hydroxamate-based inhibitors of deacetylases
03/01/2012WO2012025123A1 Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
03/01/2012WO2012025054A1 Diimidated derivative of berbamine, and preparation method therefor and use thereof
03/01/2012WO2012025010A1 Pharmaceutical composition for treating chronic liver disease and use thereof
03/01/2012WO2012024893A1 Certain chemical entities, compositions, and methods
03/01/2012WO2012024818A1 Novel anphthoquinones for disease therapies
03/01/2012WO2012024772A1 Protein-bound tryptophan food composition
03/01/2012WO2012006055A3 Compounds and methods for the treatment or prevention of flavivirus infections
03/01/2012WO2012004714A3 Benzene sulfonamides as inhibitors of voltage-gated sodium channels
03/01/2012WO2012004706A3 Chemical compounds
03/01/2012WO2012000103A8 Methods of targeting pten mutant diseases and compositions therefor
03/01/2012WO2011163358A3 Intravaginal devices comprising anticholinergic agents, and methods of making thereof
03/01/2012WO2011161537A3 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide derivatives, preparation thereof and therapeutic use thereof
03/01/2012WO2011161056A3 Dialysis precursor composition
03/01/2012WO2011154830A3 Pharmaceutical form comprising phosphodiesterase inhibitors, for transmucosal administration
03/01/2012WO2011151704A3 Stable pharmaceutical compositions of rapamycin esters
03/01/2012WO2011144745A3 Improved liposomal formulations of lipophilic compounds
03/01/2012WO2011143640A3 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
03/01/2012WO2011143457A3 Compositions and methods for treating or preventing atrial fibrillation
03/01/2012WO2011143423A3 Compounds useful as inhibitors of atr kinase
03/01/2012WO2011143271A3 Therapeutic liposomes and methods for producing and using the same
03/01/2012WO2011143262A3 Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
03/01/2012WO2011141716A3 Modulators of chk-1 activity
03/01/2012WO2011140236A3 Triamcinolone acetonide formulations for treating dermatitis and psoriasis
03/01/2012WO2011140198A3 Compounds and methods of treating brain disorders
03/01/2012WO2011139897A3 Reduction of alpha-tocopherol quinone
03/01/2012WO2011139252A3 Efervescent formulations comprising cefdinir
03/01/2012WO2011139250A3 Water dispersible formulation comprising betahistine
03/01/2012WO2011139249A3 Pharmaceutical composition comprising cefdinir
03/01/2012WO2011139079A3 Pharmaceutical composition for inhibiting apoptosis of neuron or neurodegeneration
03/01/2012WO2011139044A3 Controlled-release pharmaceutical composition including tamsulosin or the pharmaceutically acceptable salts thereof, and oral preparation including same
03/01/2012WO2011137540A8 Gfi1b modulation and uses thereof
03/01/2012WO2011137456A9 Methods and mechanisms involving hyperpigmentation particularly for african american skin
03/01/2012WO2011132085A3 Methods and compositions for treating fibrosis
03/01/2012WO2011127200A9 Methods of treatment using 3-bromopyruvate and other selective inhibitors of atp production
03/01/2012WO2011122916A9 Composition for increasing trail sensitivity, containing an inhibitor for inhibiting the expression or activity of tip41 which is a trail sensitizer target gene
03/01/2012WO2011116355A3 Benzoisothiazolones as inhibitors of phosphomannose isomerase
03/01/2012WO2011112588A9 Compositions and methods for treating inflammatory disorders
03/01/2012WO2011109809A3 A novel composition of matter for delivering lipid-soluble materials, and a method for producing it
03/01/2012WO2011109731A3 Arylfluorophosphate inhibitors of intestinal apical membrane sodium/phosphate co-transport
03/01/2012WO2011109334A3 Localization of agents at a target site with a composition and an energy source
03/01/2012WO2011106416A3 Abuse-resistant formulations
03/01/2012WO2011098582A3 Novel crystalline forms of ivabradine hydrochloride
03/01/2012WO2011095801A3 Liquid pharmaceutical composition for buccal administration comprising morphine
03/01/2012WO2011093814A3 A pharmaceutical combination comprising formoterol and ciclesonide
03/01/2012WO2011092604A3 Topical antiparasitic formulations
03/01/2012WO2011076208A3 Calcipotriol monohydrate nanocrystals
03/01/2012WO2011076207A3 Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
03/01/2012WO2011064271A3 Use of an oleo gel containing triterpene for healing wounds
03/01/2012WO2011053265A3 The parmaceutical compositions comprising calcium and vitamin d
03/01/2012WO2011051354A3 Transdermal pharmaceutical compositions comprising active agents
03/01/2012WO2011014257A9 Approaches to treat cancer using hb-egf inhibitors such as myrsinoic acid a
03/01/2012WO2011012515A3 Aqueous barrier solution for protecting skin from non-water-soluble substances
03/01/2012WO2011009193A8 Combinations of curcuminoids and mtor inhibitors for the treatment of tauopathies
03/01/2012WO2011005811A8 Combination therapy for the treatment of diabetes
03/01/2012WO2003002067A3 Inhibition of tumor growth and metastasis by n5 gene
03/01/2012US20120054920 Hyperbranched Polycarbonates for Solubilizing Poorly Soluble Active Substances
03/01/2012US20120054879 HCV Coreceptor and Methods of Use Thereof
03/01/2012US20120053559 Treatment of Proliferative Diseases with Epothilone Derivatives and Radiation
03/01/2012US20120053510 Treatment of Cardiac Arrhythmia by Modification of Neuronal Signaling Through Fat Pads of the Heart
03/01/2012US20120053509 Vaccines for human papilloma virus and methods for using the same
03/01/2012US20120053247 Method of improving cardiovascular health
03/01/2012US20120053246 Purification process for preparing highly pure arformoterol tartrate substantially free of desformyl impurity
03/01/2012US20120053245 Methods of Treating Hair Related Conditions
03/01/2012US20120053244 Alkylamido Compounds and Uses Thereof
03/01/2012US20120053243 Parakeratosis inhibitor and skin preparation for external use
03/01/2012US20120053242 Compositions rich in omega-3 fatty acids with a low content in phytanic acid
03/01/2012US20120053241 Aqueous nanoemulsion composition containing conjugated linoleic acid
03/01/2012US20120053240 Method of Administering beta-hydroxy-beta-methylbutyrate (HMB)
03/01/2012US20120053239 Treatment for intestinal gas, bloating, microscopic colitis, inflammatory bowel disease and traveler's diarrhea using colloidal bismuth subcitrate
03/01/2012US20120053238 Solid retigabine in non-crystalline form
03/01/2012US20120053237 Oligomer-Amino Acid Conjugates
03/01/2012US20120053236 Pharmaceutical composition for diabetic nephropathy and its preparation and application
03/01/2012US20120053235 Dihydromyricetin as an IKK-beta inhibitor used for treatment of arthritis, cancer and autoimmune conditions, and other diseases or disorders
03/01/2012US20120053234 Hepcidin Binding Nucleic Acids
03/01/2012US20120053232 ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF ISOLATED GENOMIC POLYNUCLEOTIDE FRAGMENTS FROM THE p15 REGION OF CHROMOSOME 11 ENCODING HUMAN TUMOR SUPPRESSING SUBTRANSFERABLE CANDIDATE 4 (TSSC4)
1 ... 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 ... 7860